Navigation Links
Abbott Advances Its Revolutionary Fully Bioabsorbable Drug Eluting Stent With Initiation of Next Phase of Clinical Trial
Date:3/24/2009

ABBOTT PARK, Ill., March 24 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT) today announced the initiation of the next phase of the ABSORB clinical trial to evaluate the safety and performance of the company's fully bioabsorbable drug eluting coronary stent. This second phase of the ABSORB clinical trial will enroll approximately 80 patients at 10 centers in Europe, Australia and New Zealand, and will incorporate device enhancements designed to improve deliverability and vessel support. The first patient was enrolled into the second stage of the ABSORB clinical trial at Onze Lieve Vrouw Ziekenhuis Hospital in Aalst, Belgium, by Bernard De Bruyne, M.D., Ph.D.

"Interventional cardiology has come a long way. It started with balloon angioplasty, which evolved into bare metal stents and then drug eluting metal stents were created," said Patrick W. Serruys, M.D., Ph.D., professor of interventional cardiology at the Thoraxcentre, Erasmus University Hospital, Rotterdam, and principal investigator of the ABSORB trial. "Now we have the fourth revolution in interventional cardiology technology, and patient outcomes from the first stage of ABSORB clearly show that bioabsorbable devices are the future of coronary artery disease treatment."

Results from the first stage of the ABSORB trial with 30 patients demonstrated that Abbott's bioabsorbable everolimus eluting stent successfully treated coronary artery disease, and that at two years, the treated vessel was able to expand and contract, without being restricted by a permanent implant - indicating that the device was absorbed. In addition, there were no cases of thrombosis (blood clot formation) out to two years of follow-up, and no new major adverse cardiac events (MACE) between six months and two years, with the bioabsorbable device demonstrat
'/>"/>

SOURCE Abbott
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. The Lancet Publishes Two-Year Results of Abbotts Fully Bioabsorbable Drug Eluting Stent
2. Abbott and Enanta Initiate Phase 1 Clinical Trial on ABT-450 HCV Protease Inhibitor
3. Abbott Receives Complete Response Letter From FDA for Controlled-Release Hydrocodone With Acetaminophen
4. Abbotts XIENCE V(TM) Drug Eluting Stent Outperforms TAXUS(R) in Key Efficacy and Safety Endpoints Out to Two Years
5. Continuous Treatment With Abbotts HUMIRA(R) Achieves Superior Long-Term Efficacy for Psoriasis Patients Compared to Interrupting Treatment
6. Abbotts Kaletra(R) Tablet Dosed Once-Daily or Twice-Daily Demonstrated Similar Clinical Results Across Race and Gender Lines
7. Abbotts Phase III Sub-Group Analysis Shows Investigational TriLipix(TM) in Combination with CRESTOR(R) Improves Key Lipids in Patients with Mixed Dyslipidemia and Type 2 Diabetes
8. Phase III Study of Abbotts Investigational TriLipix(TM) in Combination With AstraZenecas CRESTOR(R) Meets Primary Endpoints on Key Lipids
9. Abbott Presents Long-Term Data From Extension Study Showing Adult Crohns Patients Treated With HUMIRA(R) (Adalimumab) Maintained Remission
10. XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years
11. Study in JAMA Shows Patients Treated With Abbotts XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... , July 31, 2014  Today, Levi ... new extension to its PageCenterX ® content ... is designed to provide downtime reporting capabilities to ... LRS is releasing the product for general availability, ... EMR applications experience outages for a variety of ...
(Date:7/31/2014)... 2014 Orexigen® Therapeutics, Inc. (Nasdaq: ... quarter 2014, on Thursday, August 7, 2014 before markets ... webcast and conference call at 8:00 a.m. Eastern time ... host the call and webcast to discuss financial results ... accessed by calling (800) 708-4540 (domestic) or (847) 619-6397 ...
(Date:7/31/2014)... , July 31 2014  Northsight Capital, Inc. ... has been named Chairman and CEO of the company. ... management, legal matters, business development and investment banking. Mr. ... securities industry.  Before his career on Wall Street, Mr. ... of the U.S, Securities and Exchange Commission in ...
Breaking Medicine Technology:LRS Announces Downtime Reporting Solution for Healthcare 2Orexigen Therapeutics to Host Second Quarter 2014 Financial Results Conference Call and Webcast 2Northsight Capital, Inc. Names Wall Street Veteran John Bluher, Former EVP And General Counsel Of Knight Trading Group, Chairman And CEO. 2
... PALO ALTO, Calif., May 3, 2011 Jazz Pharmaceuticals, Inc. (Nasdaq: ... first quarter of 2011. Total revenues for ... to $35.2 million for the first quarter of 2010.  Total ... GAAP net income for the first quarter of 2011 ...
... 3, 2011 Coast Dental Services, Inc., announced today ... the assets of Dental Technology, Inc. (DTI), doing business ... licensed  health care service plan. DTI and its subsidiaries ... Texas, employing 1,200 staff members, including 130 dentists.  The ...
Cached Medicine Technology:Jazz Pharmaceuticals Announces First Quarter 2011 Financial Results 2Jazz Pharmaceuticals Announces First Quarter 2011 Financial Results 3Jazz Pharmaceuticals Announces First Quarter 2011 Financial Results 4Jazz Pharmaceuticals Announces First Quarter 2011 Financial Results 5Jazz Pharmaceuticals Announces First Quarter 2011 Financial Results 6Jazz Pharmaceuticals Announces First Quarter 2011 Financial Results 7Coast Dental to Acquire the Assets of SmileCare 2
(Date:7/31/2014)... news release is available in German . ... from baby blues after giving birth. Some even develop ... oxidase A, an enzyme responsible for the breakdown of ... in this condition. In comparison to healthy women, women ... the enzyme in their brains. This was discovered by ...
(Date:7/31/2014)... University medical and nursing school researchers hope to ... who participate in clinical trials, a critical step ... , For various reasonsincluding a lack of awareness ... cancer patients take part in trials of experimental ... patients who are eligible still don,t enroll, according ...
(Date:7/31/2014)... Calif. and Las Vegas, Nevada (PRWEB) July 31, 2014 ... with LaunchKey to provide next generation authentication services to ... and secure way to utilize hardware protected multi-factor authentication ... problem in the Internet's reliance on password-based authentication. It ... and global data breaches taking place around the globe. ...
(Date:7/31/2014)... FRANCISCO & ATLANTA (PRWEB) July 31, 2014 ... executive networking and relationship-marketing firm, honored finalists and ... ISE® West Executive Forum and Awards Gala at ... , Max Solonski, director of information security for ... Security Executive® of the Year Award winner for ...
(Date:7/31/2014)... HealthDay Reporter WEDNESDAY, July ... is growing increasingly resistant to the drugs commonly used to ... drugs are in development, and at least one in early ... "Although there has been considerable progress in malaria control ... from won, and there is still much more to do," ...
Breaking Medicine News(10 mins):Health News:Monoamine oxidase A: Biomarker for postpartum depression 2Health News:Monoamine oxidase A: Biomarker for postpartum depression 3Health News:$1.6 million NCI grant to CWRU trains nurses to increase participation in clinical trials 2Health News:$1.6 million NCI grant to CWRU trains nurses to increase participation in clinical trials 3Health News:Rivetz Partners with LaunchKey to Offer Next Generation Authentication for Accounts Leveraging Trusted Execution Technology. 2Health News:Rivetz Partners with LaunchKey to Offer Next Generation Authentication for Accounts Leveraging Trusted Execution Technology. 3Health News:Max Solonski, Caesars Entertainment Claim Top Awards at ISE® West Ralph Johnson (King County, WA) named People’s Choice Award Winner 2Health News:Max Solonski, Caesars Entertainment Claim Top Awards at ISE® West Ralph Johnson (King County, WA) named People’s Choice Award Winner 3Health News:Max Solonski, Caesars Entertainment Claim Top Awards at ISE® West Ralph Johnson (King County, WA) named People’s Choice Award Winner 4Health News:Malaria Growing Resistant to Drugs Used to Fight It 2Health News:Malaria Growing Resistant to Drugs Used to Fight It 3
... Each year about 400,000 Americans undergo balloon angioplasty to clear ... Now, a cancer drug may change the outcome of the ... doing everything he can to avoid a second open-heart surgery. ... ,But earlier this year, Bailey had the same ...
... late at night, when hunger strikes may seem a familiar ... people do // not eat enough throughout the day. People ... tend to crave carbs and sweets . ,Studies show ... and angry. When these same people resume normal eating habits, ...
... Based on the results of a recent study researchers ... value of stretching before exercising.// Specialists say stretching does ... research shows static stretching makes muscles weaker for 10 ... of injury. They say some likely causes of injuries ...
... to an increased risk of breast cancer say researchers based ... who experienced a short, but severe decrease in food intake ... breast cancer than women not affected by the famine. ... Dutch famine participated in the Dutch breast cancer screening program ...
... blindness in the United States. It affects the blood vessels ... at the back of the eye. Retinopathy occurs in most ... with aggressive control of blood glucose and blood pressure. New ... suffer from diabetic retinopathy, and that number is expected to ...
... Neuro scientists say new findings in animals suggest a ... other nervous system injuries . ,"Our approach is ... themselves,// called the stress protein response," say specialists . ... prevent or minimize the "secondary" cell death that occurs ...
Cached Medicine News:Health News:New Findings Could Reduce The Extent Of Spinal Cord Injuries 2
... supply is the latest edition ... offering. It sets new standards ... This product has unique features ... as microAmp detector, display and ...
... as a constant voltage power supply, the 105 ... and hilo range switch control the output, which ... 250 volts. One, two-position switch toggles the bright ... current. The 105 is equipped with an over ...
... power supply is capable of producing up to ... product operates in constant voltage or constant current ... crosses over from one mode of operation to ... A dual function, auto ranging 24-hour ...
... designed for horizontal and vertical gel electrophoresis ... accomplished. In this power supply model, output ... or constant voltage. Four sets of output ... simultaneously. This power supply's light, compact and ...
Medicine Products: